Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma Equity Group AS's book value per share for the quarter that ended in Dec. 2025 was kr0.02.
During the past 12 months, Pharma Equity Group AS's average Book Value Per Share Growth Rate was -22.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -74.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -63.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -44.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Pharma Equity Group AS was -7.20% per year. The lowest was -74.30% per year. And the median was -29.50% per year.
Pharma Equity Group AS (OCSE:PEG) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Pharma Equity Group AS Book Value per Share Related Terms
Pharma Equity Group AS Book Value per Share Historical Data
* Premium members only.
The historical data trend for Pharma Equity Group AS's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:PEG vs VRTX, REGN, RVMD: Book Value per Share Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Equity Group AS (OCSE:PEG) has a Book Value per Share of kr0.02 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Pharma Equity Group AS and its competitors.
Is Pharma Equity Group AS's Book Value per Share too high?
Pharma Equity Group AS's current Book Value per Share is kr0.02.
How does Pharma Equity Group AS's Book Value per Share compare to VRTX and REGN?
Pharma Equity Group AS's Book Value per Share of kr0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Pharma Equity Group AS and its competitors. Pharma Equity Group AS's current Book Value per Share is kr0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Book Value per Share of kr0.02. The current Book Value per Share is kr0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Book Value per Share is kr0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 
